C5aR2 Deficiency Ameliorates Inflammation in Murine Epidermolysis Bullosa Acquisita by Regulating Fcγ Receptor Expression on Neutrophils

Daniel Leonard Seiler¹,², Marie Kleingarn¹, Katja Hendrika Kähler¹, Caroline Gruner¹, Jovan Schanzenbacher¹, Elvira Ehlers-Jeske¹, Samyr Kenno¹, Christian David Sadik³,⁴, Enno Schmidt³,⁴,⁵, Katja Bieber³,⁴,⁵, Jörg Köhl¹,⁶, Ralf J. Ludwig³,⁴,⁵ and Christian Marcel Karsten¹

Epidermolysis bullosa acquisita (EBA) is a rare blistering skin disease induced by autoantibodies directed against type VII collagen. The transfer of antibodies against murine type VII collagen into mice mimics the effector phase of EBA and results in a subepidermal blistering phenotype. Activation of the complement system, and especially the C5a/C5aR1 axis driving neutrophil activation, is critical for EBA pathogenesis. However, the role of the alternative C5a receptor, C5aR2, which is commonly thought to be more immunosuppressive, in the pathogenesis of EBA is still elusive. Therefore, we sought to delineate the functional relevance of C5aR2 during the effector phase of EBA. Interestingly, C5ar2⁻/⁻ mice showed an attenuated disease phenotype, suggesting a pathogenic contribution of C5aR2 in disease progression. In vitro, C5ar2⁻/⁻ neutrophils exhibited significantly reduced intracellular calcium flux, ROS release, and migratory capacity when activated with immune complexes or exposed to C5a. These functions were completely absent when C5ar1⁻/⁻ neutrophils were activated. Moreover, C5aR2 deficiency lowered the ratio of activating and inhibitory FcγRs, impeding the sustainment of inflammation. Collectively, we show here a proinflammatory contribution of C5aR2 in the pathogenesis of antibody-induced tissue damage in experimental EBA.

INTRODUCTION

Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering disease of the skin, characterized and caused by autoantibodies targeting type VII collagen (COL7) (Koga et al., 2019; Schmidt and Zillikens, 2013). The activation of the complement system during the effector phase of the disease is considered a central pathogenic process (Kasperkiewicz et al., 2019; Schmidt and Zillikens, 2013). The activation of antibodies targeting type VII collagen (COL7) (Koga et al., 2019) results in a subepidermal blistering phenotype. Activation of the complement system during the effector phase of EBA. Interestingly, C5ar2⁻/⁻ mice showed an attenuated disease phenotype, suggesting a pathogenic contribution of C5aR2 in disease progression. In vitro, C5ar2⁻/⁻ neutrophils exhibited significantly reduced intracellular calcium flux, ROS release, and migratory capacity when activated with immune complexes or exposed to C5a. These functions were completely absent when C5ar1⁻/⁻ neutrophils were activated. Moreover, C5aR2 deficiency lowered the ratio of activating and inhibitory FcγRs, impeding the sustainment of inflammation. Collectively, we show here a proinflammatory contribution of C5aR2 in the pathogenesis of antibody-induced tissue damage in experimental EBA.


Abbreviations: A/I ratio, ratio between activating and inhibitory FcγRs; AUC, area under the curve; BM, bone marrow; (Ca²⁺), intracellular calcium; COL7, type VII collagen; EBA, epidermolysis bullosa acquisita; IC, immune complex; mCOL7, murine type VII collagen; MFI, mean fluorescence intensity; WT, wild-type

Received 23 February 2021; revised 6 December 2021; accepted 17 December 2021; accepted manuscript published online 7 January 2022; corrected proof published online 21 August 2022
immunomodulatory signals and modulate cellular responses (Bamberg et al., 2010; Croker et al., 2014; Kalant et al., 2005; Van Lith et al., 2009). Unlike C5aR1, C5aR2 does not engage intracellularly with G proteins and therefore signals in a G protein-independent fashion (Okinaga et al., 2003). However, C5aR2 can directly recruit β-arrestin 2 and also modulate the recruitment of β-arrestin 2 to C5aR1 (Croker et al., 2014; Kalant et al., 2005). The C5aR2—β-arrestin 2 interaction results in decreased C5a-mediated extracellular signal—regulated kinase 1/2 phosphorylation and lipopolysaccharide-induced production of IL-6 in myeloid cells (Croker et al., 2016). Furthermore, C5aR2 has been shown to oppositely modulate disease progression in a pro-inflammatory model (Poppelaars et al., 2017; Rittirsch et al., 2008; Thorenz et al., 2018; Zhang et al., 2010) or anti-inflammatory (Gerard et al., 2005; Wang et al., 2013; Wu et al., 2020) manner in various inflammatory models, depending on the disease model studied (Zhang et al., 2017).

Neutrophils drive cellular effector responses in a range of antibody-mediated diseases, including EBA (Chiriac et al., 2007; Girardi et al., 2003; Looney et al., 2006; Samavedam et al., 2014; Sezin et al., 2017; Shimanovich et al., 2004; Sitaru et al., 2005; Wipke and Allen, 2001). Because we previously noted a high expression of C5aR2 on neutrophils (Karsten et al., 2017), we investigated the previously unexplored potential role of C5aR2 in experimental EBA.

RESULTS
Experimental EBA is ameliorated in C5ar2−/− mice
C5ar2−/− and wild-type (WT) mice were injected with affinity-purified rabbit IgG directed against murine COL7 (mCOL7) to induce experimental EBA. Mice of both genotypes showed first clinical signs of skin blistering from day 4 onward after anti-mCOL7 IgG injection. However, disease progression was ameliorated in C5ar2−/− mice from day 6 onward (Figure 1a), and by day 12, C5ar2−/− mice displayed significantly reduced areas of blister-affected skin (7.6 ± 0.7%) compared with that in WT mice (13.1 ± 0.8%). Accordingly, the cumulative disease severity, expressed as area under the curve (AUC) over time, was also significantly reduced in C5ar2−/− mice (Figure 1b). Skin blisters and signs of inflammation were also evident in lesional skin sections of the ear, characterized by tissue swelling and cellular infiltration (Figure 1e–h), suggesting strongly disseminated disease (Figure 1c and d).

Anti-mCOL7 IgG and C3b deposition at the dermal–epidermal junction are not altered in C5ar2−/− mice
To exclude the possibility that the observed difference in disease activity between WT and C5ar2−/− mice may be due to inherent changes of IgG deposition or complement activation in the knock-out animals, cryosections from ears were examined by direct immunofluorescence microscopy for COL7 IgG and C3b deposition at the dermal–epidermal junction. We observed no significant differences between C5aR2-sufficient or -deficient mice for rabbit anti-mCOL7 IgG or C3b deposits at the dermal–epidermal junction (Figure 2).

Neutrophils from C5ar2−/− mice show significantly reduced cellular activation on stimulation with C5a
Neutrophils abundantly express C5aR2 and are central to EBA development. We therefore next assessed whether neutrophils lacking C5aR2 may respond differently to stimulation with C5a. For this, bone marrow (BM) cells were isolated from naive, nondiseased WT or C5ar2−/− mice and
examined for C5a-mediated effector functions as indicated by an increase in intracellular calcium (Ca\(^{2+}\)) influx and upregulation of CD11b; events normally induced by neutrophils exposed to C5a. Ly6G\(^{+}\) BM cells (Figure 3a) lacking C5aR2 showed a significantly blunted (Ca\(^{2+}\)) flux compared with Ly6G\(^{+}\) BM cells isolated from WT mice (WT: 44.3/\(\pm\)5.0%; C5ar2\(^{-/-}\): 20.3/\(\pm\)4.1%). As expected, neutrophils derived from C5ar1\(^{-/-}\) mice displayed fully abrogated (Ca\(^{2+}\)) flux after C5a stimulation (Figure 3b). We made similar observations when measuring surface expression levels of CD11b after stimulation with C5a: Ly6G\(^{+}\) BM cells from C5ar2\(^{-/-}\) mice showed a strong reduction in CD11b upregulation (171.2/\(\pm\)19.5%) compared with Ly6G\(^{+}\) BM cells from WT mice (214.3/\(\pm\)9.3%), whereas CD11b surface expression in Ly6G\(^{+}\) BM cells from C5ar1\(^{-/-}\) mice remained nondetectable after stimulation with C5a (Figure 3c). These findings were also confirmed for Ly6G\(^{+}\) cells from the BM of WT and C5ar2\(^{-/-}\) mice after EBA induction (Supplementary Figure S1a and b).

Thus, these data show that neutrophils, devoid of C5aR2 expression, have a reduced activation profile on stimulation with C5a in vitro.

**Immune complex-induced ROS release is significantly decreased in C5ar2\(^{-/-}\) neutrophils**

To determine whether the difference in the disease activity between WT and C5ar2\(^{-/-}\) mice may also be due to diminished ROS release by C5ar2\(^{-/-}\) neutrophils, ROS release by isolated BM cells was analyzed after stimulation with an immune complex (IC) composed of mCOL7C and rabbit anti-mCOL7 IgG, mimicking the disease-inducing IC in the EBA mouse model. BM cells from naive, nondiseased mice of both genotypes released ROS within the first 30 minutes after stimulation with the IC (data not shown). However, relative ROS release by neutrophils from C5ar2\(^{-/-}\) mice was significantly decreased (relative AUC: 2.09/\(\pm\)0.26) compared with cells from WT mice (relative AUC: 2.61/\(\pm\)0.23; Figure 3d).

Thus, these data show that the loss of C5aR2 expression on neutrophils results in decreased ROS release on stimulation with ICs in vitro.

**Neutrophils lacking C5aR2 show significantly lower migration toward C5a**

We next assessed whether the migratory capacity toward a C5a gradient may also be affected by C5aR2 deficiency, using an established in vitro transwell migration experiment. Indeed, the percentage of chemotactic Ly6G\(^{+}\) BM cells was significantly lower in C5ar2\(^{-/-}\) mice (28.5/\(\pm\)4.0%) compared with that in corresponding cells isolated from WT mice (40.3/\(\pm\)4.6%). Approximately 9.5/\(\pm\)1.6% of seeded Ly6G\(^{+}\) BM cells derived from C5ar1\(^{-/-}\) control mice transmigrated into the bottom well, which basically represented the baseline or background value (control: 9.9/\(\pm\)1.3%; Figure 3e). To probe for neutrophil migration in vivo, the number of neutrophils in the blood and among the infiltrating...
cells into the ears of WT and C5ar2−/− mice was quantified after EBA induction. Blood neutrophil count and infiltrating immune cells in the ears of diseased mice were significantly higher than that in naive, nondiseased WT control mice (Supplementary Figure S2). We also noted a nonsignificant trend toward higher immune cell numbers in WT mice than the numbers in C5ar2−/− mice, 12 days after EBA induction (Supplementary Figure S2).

C5aR1 expression in neutrophils is not altered by C5aR2 deficiency
To determine whether the effects on the activation potential and migration behavior observed in the different in vitro-settings were due to an effect of C5aR2 deficiency on C5aR1 (CD88) expression, surface expression of C5aR1 on neutrophils of the different genotypes was assessed by flow cytometry. As shown in Figure 4a, C5aR1 expression in Ly6G+ neutrophils from naive, nondiseased C5ar2−/− mice was similar to that in WT mice. These findings were also confirmed for Ly6G+ cells from BM of diseased mice (Supplementary Figure S1c).

Neutrophils from C5ar2−/− mice exhibit an altered ratio of activating and inhibitory FcγRs
Previous studies showed that subepidermal blister formation depends on the interaction between COL7/anti-mCOL7 IgG ICs and activating FcγRs, namely FcγRIII and FcγRIV, whereas inhibitory FcγRIIb is protective in EBA (Kasperkiewicz et al., 2012; Kovacs et al., 2020). Therefore, we analyzed the expression profiles of FcγRIIb, FcγRIII, and FcγRIV on neutrophils from WT and C5ar2−/− mice in the nondiseased state. The respective expression profiles of the activating receptors, FcγRIII and FcγRIV, were comparable between WT and C5ar2−/− mice in the steady state. However, surface expression of FcγRIIb was significantly augmented in Ly6G+ BM cells isolated from naive, nondiseased C5ar2−/− mice when compared with that in the corresponding cells from WT mice. This effect was not observed in neutrophils from C5ar1−/− mice, which maintained unchanged expression of FcγRs compared with those from WT mice (data not shown). Specifically, surface expression of FcγRIIb was more than 3-fold increased on Ly6G+ BM cells from naive, nondiseased C5ar2−/− mice (mean fluorescence intensity [MFI]):

Figure 3. C5a-mediated activation potential and migration behavior is significantly diminished in neutrophils of C5ar2−/− mice. (a) Flow cytometric gating strategy to identify neutrophils as Ly6G+ live BM cells from naive, nondiseased mice. (b) C5a-dependent changes in (Ca2+)i concentration as an indicator of cellular activation quantified by changes in fluorescence intensity of the calcium-sensitive compound Fluo-4 over the time (n = 8 per group). (c) C5a-mediated activation of neutrophils quantified by upregulation of surface expression of CD11b (n ≥ 8 per group). (d) IC-induced release of ROS from BM cells (n ≥ 9 per group). (e) Percentage of chemotactic Ly6G+ BM cells in an in vitro migration assay toward C5a (n = 5 per group). Shown are combined data from at least three independent experiments, each performed with 2–3 mice per genotype. Differences between groups were analyzed by ordinary one-way ANOVA with Holm-Sidak multiple comparisons test for (b–e). AUC, area under the curve; BM, bone marrow; (Ca2+)i, intracellular calcium; FSC, forward scatter; FVD, fixable viability dye; IC, immune complex; mCOL7, murine type VII collagen; mCOL7C, recombinant murine type VII collagen C; MFI, mean fluorescence intensity; neg., negative control; n.s., not significant; pos., positive control; WT, wild-type. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
6,936 ± 159) compared with WT cells (MFI: 1,806 ± 102; Figure 4b). Consequently, the ratio between activating and inhibitory FcγRs (A/I ratio), that is, the balance between activating and inhibitory FcγRs, was tipped toward the inhibitory receptor in neutrophils lacking C5aR2. This altered balance contributed to the muted ROS release by neutrophils from C5ar2<sup>−/−</sup> mice, as the blockade of FcγRIIB by an inhibitory antibody rescued ROS release in IC-stimulated C5ar2<sup>−/−</sup> neutrophils: ROS release from C5ar2<sup>−/−</sup> BM cells was increased by 32.6 ± 2.7% after the blockade of FcγRIIB (Figure 4c).

To verify whether the lower A/I ratio of FcγRs expression by neutrophils from C5ar2<sup>−/−</sup> mice is sustained in EBA disease induction, the expression of FcγRs on neutrophils from BM and blood of diseased mice was analyzed 12 days after anti-mCOL7 IgG injection. Neutrophils from both sites in the C5ar2<sup>−/−</sup> mice showed a significant increase in FcγRIIB expression (MFI BM: 5,515 ± 124; MFI blood: 7,826 ± 212). Furthermore, different from nondiseased mice, FcγRIV expression was significantly lower in both Ly6G<sup>+</sup> cells of the BM (MFI: 3,115 ± 78) and blood (MFI: 3,785 ± 256; Figure 4d) from diseased C5ar2<sup>−/−</sup> mice compared with that in the matching cells from WT mice. In addition, Ly6G<sup>+</sup> BM cells from diseased mice of both genotypes increased the expression of activating FcγRs, FcγRIII and FcγRIV, after BM to blood transition. However, blood neutrophils from diseased WT mice showed a slightly decreased expression of FcγRIIB compared with their BM counterparts, whereas blood neutrophils from diseased C5ar2<sup>−/−</sup> mice further increased their FcγRIIB expression and reached a 5-fold increase in FcγRIIB expression (MFI: 7,826 ± 212) compared with the corresponding WT mice (MFI: 1,563 ± 36; Figure 4e-f).

Thus, these data show that C5aR2 deficiency shifts the A/I ratio on neutrophils toward an inhibitory phenotype, resulting in decreased IC-induced ROS release.

**DISCUSSION**

Insight into the pathogenesis of EBA has been gained by the use of animal models (Bieber and Ludwig, 2020; Kasprick et al., 2019; Nishie, 2014). The antibody transfer animal model has been utilized to discover and define the importance of C5aR1 in the pathogenesis of EBA (Karsten et al., 2012; Mihai et al., 2018). The main objective of this study was to elucidate whether C5aR2 has functional properties relevant to the progression of EBA. For this purpose, we also
chose the antibody transfer EBA mouse model, which mimics the effector phase of the disease.

The finding that disease activity was significantly lower in C5ar2<sup>e<sup>−/−</sup> mice than in WT mice was surprising because C5ar2 had previously been shown to be protective in an antibody transfer model of bullous pemphigoid (Karsten et al., 2018). This difference might be explained by the fact that the pathomechanisms in bullous pemphigoid are slightly different from those in EBA with autoantibodies directed against the hemidesmosomal components BP180 (type XVII collagen) and BP230 (Schmidt and Zillikens, 2013). This notion is supported by the different roles of FcγRIII and C5 in the two antibody transfer mouse models. Although in the EBA model, only FcγRI, but not FcγRII, is relevant for antibody-mediated tissue destruction, and C5<sup>e<sup>−/−</sup> mice are almost completely protected (Kasperkiewicz et al., 2012; Sitaru et al., 2005); in the bullous pemphigoid mouse model, both FcγRIII and FcγRI drive tissue destruction, and C5<sup>e<sup>−/−</sup> mice showed a decrease in skin lesions by 50% compared with WT mice (Karsten et al., 2018; Schulze et al., 2014). In addition and in contrast to this study, the aforementioned study used C5ar2<sup>e<sup>−/−</sup> and WT mice on a BALB/c background. Interestingly, WT mice on a C5<sup>e<sup>−/−</sup>BL/6 background developed stronger signs of skin blistering than WT mice on a BALB/c background (Karsten et al., 2018), which might be explained by the differences in the C5 circulating levels between these strains (Lajoie et al., 2010).

Lipid and complement mediators have previously been shown to influence the course of pathogenesis of (auto-) antibody-induced diseases by modulating the infiltration of effector cells into the skin (Koga et al., 2019; Sadik et al., 2012; Sezin et al., 2017). Among the complement components involved, C5a, the most potent anaphylatoxin of our immune system, plays a key role. Therefore, reduced mobilization and/or recruitment of neutrophils into the skin was initially a plausible potential explanation for the reduced EBA disease activity in C5ar2<sup>e<sup>−/−</sup> mice. Moreover, in C5ar2<sup>e<sup>−/−</sup> mice, reduced inflammation was also noted in models of thio-glucolate peritonitis and intestinal ischemia—reperfusion injury, which also depend on normal neutrophil migration (Chen et al., 2007; Wu et al., 2020). In addition, mobilization of neutrophils from the BM is impaired in C5ar2<sup>e<sup>−/−</sup> mice (Wu et al., 2020). In IC-induced arthritis, C5aR2 is required for the trans-epithelial transport of tissue-derived C5a into the blood lumen to induce leukocyte entry into the joint (Miyaie et al., 2019). Although BM-derived neutrophils from naïve, non-diseased C5ar2<sup>e<sup>−/−</sup> mice showed a significantly reduced chemotaxis toward C5a in vitro (Figure 3e), we unexpectedly observed a nonstatistical trend toward reduced numbers of neutrophils in the blood and skin of diseased C5ar2<sup>e<sup>−/−</sup> mice compared with that in the blood and skin of WT mice (Supplementary Figure S2). The reasons for this finding are still unclear; however, it is possible that in this particular in vivo disease model, C5aR1 activity mediates neutrophil migration successfully. Of note, in a previous work, we found no significant reduction in the chemotactic activity of neutrophils from C5ar2<sup>e<sup>−/−</sup> mice compared with that of neutrophils from WT mice in vitro (Karsten et al., 2018). This discrepancy is best explained by the different detection methods used to enumerate migrated neutrophils, namely the manual counting previously and flow cytometry in this study, which constitutes a more sensitive and unbiased approach.

Nonetheless, we found that C5a-induced cellular activation was significantly reduced in neutrophils from C5ar2<sup>e<sup>−/−</sup> mice compared with that in neutrophils from WT mice, consistent with previous data showing impaired C5a-mediated Mac-1 (CD11b/CD18) induction in C5ar2<sup>e<sup>−/−</sup> neutrophils (Chen et al., 2007). Moreover, C5a-induced cellular activation was completely absent in C5ar1<sup>e<sup>−/−</sup> neutrophils, supporting the notion that C5aR1 engagement by C5a is mandatory for normal neutrophil activity in these experimental settings. Considering the known signaling interactions between C5aR1 and C5aR2 among several cell types, and the strong reduction in C5ar2<sup>e<sup>−/−</sup> neutrophil (which express C5aR1) activation, it is likely that C5aR2 stimulation enhances C5aR1 activities. This enhancing effect may result from heterodimer formation between the two C5a receptors as previously described but clearly requires future experimental exploration (Croker et al., 2014, 2013).

Excitingly, we found a second mechanism that accounts for blunted neutrophil activity in C5ar2<sup>e<sup>−/−</sup> mice. Neutrophils from C5ar2<sup>e<sup>−/−</sup> animals exhibited a strong decrease in the A/I ratio of FcyRs (Figure 4b, d, and e), which is known to suppress inflammation triggered by (auto-) antibodies (Bussel, 2000; Nimmerjahn and Ravetch, 2008). It has been previously proposed that there is critical bidirectional crosstalk between C5a and FcyR activation on cells expressing both receptor families, including neutrophils. According to previously observed data, IC-induced generation of C5a can lead to upregulation of activating FcyRs and downregulation of inhibitory FcyRIIb on myeloid cells (Godau et al., 2004; Karsten et al., 2012; Kumar et al., 2006; Shushakova et al., 2002). The ensuing change in the A/I ratio toward the activating phenotype thus primes cells for an inflammatory response through a self-amplifying feedback loop (Atkinson, 2006; Karsten and Köhl, 2012; Kumar et al., 2006; Schmidt and Gessner, 2005). Furthermore, it has been proposed that the crosstalk between C5a and FcyR on neutrophils not only triggers cellular activation but also sustains neutrophil recruitment in vivo (Sadik et al., 2012). Using a mouse model of IC-induced arthritis, it has been shown that activation of C5a receptor(s) on neutrophils leads to the release of LTβ and early recruitment of neutrophils to the joint, whereas FcγR engagement on neutrophils induces the release of IL-1β and subsequent production of chemokines, to ensure sustained tissue inflammation (Chou et al., 2010; Sadik et al., 2012). Our data suggest that, at least in the EBA model, C5aR2 normally supports this IC/C5a-induced inflammatory priming, mainly through altering the expression of FcyRs.

Clearly, further studies are needed to elucidate the underlying molecular mechanisms of FcyR regulation by C5aR2 in inflammatory diseases. This may be especially relevant as the magnitude of FcyRs immune response modulation is strictly isotype-dependent (Nimmerjahn and Ravetch, 2006).

In summary, our study shows that C5aR2 is critically involved in the pathogenesis of EBA. The disease phenotype of C5ar2<sup>e<sup>−/−</sup> mice in the antibody transfer EBA model partially resembles to that observed in C5ar1<sup>e<sup>−/−</sup> mice in the same model but in a more muted form (Mihai et al., 2018). Our data indicate that C5aR1 is the major control node here, but
C5aR2 enhances or supports C5aR1-driven EBA pathologies. In addition, we also found a previously unknown regulatory function of C5aR2, specifically the regulation of FcγR expression levels. Together, these C5aR2 functions sustain the recruitment and activation of neutrophils in EBA. Deciphering the molecular mechanisms driving this regulatory function of C5aR2 may be key to uncovering novel pathways of the bidirectional crosstalk between C5a and FcγRs, which will then provide information for future approaches to develop new therapeutic strategies for the treatment of C5a-dependent neutrophil-driven (autoimmune) diseases like EBA.

**MATERIALS AND METHODS**

**Mice and study approach**

C57BL/6j (WT) and C5ar2−/− mice on the C57BL/6j genetic background were bred and housed in a 12-hour light-dark cycle at the University of Lübeck animal facility (Lübeck, Germany). All infections were performed on 8- to 12-week-old anesthetized mice of both sexes. Animal experiments were conducted in strict compliance with the German regulations of the Society for Laboratory Animal Science and the European Health Law of the Federation of Laboratory Animal Science Associations. All animal experiments were approved by the respective local ethics committees for animal experiments of the state of Schleswig-Holstein (Ministerium für Energiewende, Landwirtschaft, Umwelt, Natur und Digitalisierung des Landes Schleswig-Holstein). The approval number is 106-10/19.

**Antibody transfer-induced EBA mouse model**

Affinity-purified rabbit anti-mCOL7 IgG or normal rabbit serum IgG (see Supplementary Materials and Methods) was injected subcutaneously in C57BL/6j (WT) and C5ar2−/− (on C57BL/6j background) mice of both sexes every other day for a period of four days (three injections in total) in individual doses of 100 μg IgG. Beginning with the first injection (day 0), mice were weighed and examined every other day for general condition and evidence of cutaneous lesions (i.e., erythema, blisters, erosions, and crusts). Cutaneous lesions were scored as skin surface involvement, as previously described (Kasprick et al., 2019). Blood was drawn on day 12, and both lesional and perilesional biopsies (stored at −80 °C) were collected for histopathologic analysis and direct immunofluorescence. Blood samples were prepared for quantitative immunophenotyping by flow cytometry.

**Histopathology**

Sections (6 μm) from ear skin samples were collected and differentially stained using the Kwik-Diff Stain Kit (Thermo Fisher Scientific, Waltham, MA) following the manufacturer’s protocol. Staining was analyzed using a Keyence BZ-X810 all-in-one fluorescence microscope (Keyence, Osaka, Japan) and BZ-X800 viewer software (Keyence), applying white balance to the whole image.

**Immunofluorescence microscopy**

Tissue-bound antibodies and complement deposition (C3b) were detected by direct immunofluorescence of frozen sections (8 μm) in TissueTek (Sakura Finetek Germany, Staufen im Breisgau, Germany), using FITC-conjugated swine anti-rabbit IgG (B.33 μg/ml; Dako Deutschland, Hamburg, Germany) and FITC-conjugated murine anti-mouse C3 (66.6 μg/ml; MP Biomedicals, Solon, OH), respectively. The compared samples were stained on the same day to exclude influences of day-to-day variations.

Staining was evaluated using a Keyence BZ-X810 all-in-one fluorescence microscope and BZ-X800 viewer software with identical settings for all samples. MFIs corresponding to the deposition of rabbit IgG and C3b were quantified in the acquired images without post-processing, using the ImageJ software (http://rsweb.nih.gov/ij/; National Institutes of Health, Bethesda, MD), as previously described (Kovacs et al., 2020). Briefly, the dermal–epidermal junction as the site of deposition of IgG and C3b was identified in a bright field. Staining intensities at the dermal–epidermal junction were measured with the area tool, and a reference area of the epidermis was subtracted from this value to determine background-corrected ΔMFI–anti-mCOL7 IgG or ΔMFI–C3b intensity values.

**BM cell preparation**

Mouse BM cells were isolated as previously described (Karsten et al., 2014). Briefly, BM cells were isolated from femurs and tibiae by flushing the bones with Dulbecco’s PBS using a 27G needle. After passing through a 40-μm cell strainer, red blood cells were lysed with hypotonic red blood cell lysis buffer (155 mM ammonium chloride, 10 mM potassium bicarbonate, and 0.1 mM EDTA at pH 7.2). Isolated BM cells were kept in Dulbecco’s PBS or complete RPMI-1640 medium (RPMI-1640 medium containing 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin) until further use.

**Assessment of (Ca2+)i changes in BM neutrophils**

In this assay, the increase in (Ca2+)i concentration of neutrophils (Ly6G+ cells) from isolated BM cells from C57BL/6j (WT), C5ar1−/−, and C5ar2−/− (both on C57BL/6j background) mice was measured after stimulation with recombinant C5a (Hyrcult Biotech, Uden, Netherlands), as previously described (Karsten et al., 2014). Briefly, after staining of the cells with neutrophil surface markers and the calcium-sensitive compound Fluo-4, changes in (Ca2+)i concentration were detected by measuring the change in the FITC signal from Ly6G+ cells on a BD LSRII flow cytometer (BD Biosciences, Franklin Lakes, NJ) after the addition of C5a to a final concentration of 0.2 nM. The increase in (Ca2+)i concentration was quantified by calculating the relative increase in the AUC of the Fluo-4 signal after the addition of C5a. Details are mentioned in Supplementary Materials and Methods.

**ROS release assay**

In this assay, intra- and extracellular ROS of neutrophils was measured using luminal-amplified chemiluminescence after stimulation with ICs or various controls, on the basis of previous descriptions (Yu et al., 2010). Briefly, white 96-microwell plates (Greiner Bio-One, Frickenhausen, Germany) were coated with mCOL7C or ζ-mCOL7 IgG ICs. After washing with blocking buffer, 200 μl of freshly isolated BM cells (2.5 × 106 cells/ml in CL medium) were added well per. Finally, luminol (Sigma-Aldrich, St. Louis, MO) was added to each well at a final concentration of 100 μg/ml. mCOL7C or ζ-mCOL7 alone was used as negative controls. Phorbol-12-myristate-13-acetate (Sigma-Aldrich) at a final concentration of 10 μg/ml was used as a positive control. Luminescence, corresponding to the amount of ROS released, was measured using a Fluostar Omega ELISA reader (BMG LABTECH, Ortenberg, Germany). ROS release was quantified as the increase in the AUC of luminescence relative to the positive control AUC (phorbol-12-myristate-13-acetate). Details are mentioned in Supplementary Materials and Methods.
Neutrophil chemotaxis assay
The chemotactic behavior of neutrophils (Ly6G+ cells) from C57BL/6j (WT), C5ar1−/−, and C5ar2−/− (both on C57BL/6j background) mice toward C5a was assayed using transwell inserts, as previously described (Xia et al., 2019). Briefly, 2 × 10^4 isolated BM cells were seeded onto a transwell insert with 3 μm pores (Corning, Kennebunk, ME). C5a was added to the bottom well at a final concentration of 12.5 nM, and cells were incubated at 37 °C, 5% carbon dioxide for 3 hours. Nonmigrated cells from the transwell insert and migrated cells from the bottom well were recovered, stained for Ly6G, and analyzed using a BD LSRII flow cytometer. The percentage of chemotactic neutrophils was calculated by dividing the number of migrated Ly6G+ cells by the total number of recovered neutrophils from the transwell insert and the respective bottom well. As a control, isolated BM cells were seeded onto a transwell insert without the addition of C5a to the bottom well to correct for cells that passed through the pores due to chemokinesis.

Statistical analysis
Statistical analysis of data was performed using GraphPad Prism version 9.2.0 (GraphPad Software, San Diego, CA). All data in the graphs are presented as means ± SEM. P-values were determined by unpaired t-tests for comparisons between two independent groups, ordinary one-way ANOVA with Holm–Sidak multiple comparison test for comparisons between more than two independent groups, and two-way ANOVA with Holm–Sidak multiple comparison test for comparisons including different time points or expression levels of different markers. Differences between groups was considered significant if the P-value was <0.05 (**P < 0.01, ***P < 0.001, and ****P < 0.0001).

Data availability statement
No datasets were generated or analyzed during this study.

ORCIDs
Daniel Leonard Seiler: http://orcid.org/0000-0001-5533-9237
Marie Kleingarn: http://orcid.org/0000-0002-2291-4693
Katja Hendrika Kähler: http://orcid.org/0000-0001-7356-3494
Caroline Gruner: http://orcid.org/0000-0003-4596-4453
Joan Schanzenbacher: http://orcid.org/0000-0001-5956-1142
Elvira Ehlers-Jeske: http://orcid.org/0000-0002-8223-0779
Samy Kenna: http://orcid.org/0000-0002-9448-7344
Christian David Sadik: http://orcid.org/0000-0001-6701-048X
Enno Schmidt: http://orcid.org/0000-0002-1206-8913
Katja Bieber: http://orcid.org/0000-0002-3855-6683
Jörg Köhl: http://orcid.org/0000-0003-1121-3178
Ralf J. Ludwig: http://orcid.org/0000-0002-1394-1737
Christian Marcel Karsten: http://orcid.org/0000-0003-3893-5277

CONFLICT OF INTEREST
The authors state no conflict of interest.

ACKNOWLEDGMENTS
DLS wishes to thank Claudia Kemper and Andreas Hutloff for critical feedback on the revised manuscript and all colleagues who contributed to this study. The study was supported by CRU303 TP4 given to CMK and ES. The grant number is KA 2812/2-1.

AUTHOR CONTRIBUTIONS
Conceptualization: CMK, DLS, RJL, CDS, JK, ES; Funding Acquisition: CMK, ES; Investigation: DLS, MK, KHK, CG, JS, EJ; Project Administration: DLS, CMK; Resources: RJL, KB, JK, SK; Supervision: DLS, CMK; Writing - Original Draft Preparation: DLS; Writing - Review and Editing: DLS, RJL, ES, SK, JK, CDS, CMK

SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at www.jidonline.org, and at https://doi.org/10.1016/j.jid.2021.12.029.

REFERENCES


This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

www.jidonline.org
**SUPPLEMENTARY MATERIALS AND METHODS**

**Antibodies**

For the antibody transfer model, rabbit anti-murine type VII collagen IgG was used, which was produced and purified as described (Bieber et al., 2016). For direct immunofluorescence, FITC-conjugated anti-rabbit IgG (8.33 μg/ml; Dako Deutschland, Hamburg, Germany) and FITC-labeled antimouse C3 (66.6 μg/ml; Cappel, MP Biomedicals, Solon, OH) were used. DAPI (5 mg/ml; Life Technologies, Carlsbad, CA) was used to stain the nuclei in all immunofluorescence staining. For flow cytometric analyses, FcγRs were blocked with anti-mouse CD16/CD32 (5 μg/ml; 93, Life Technologies). In addition, PE-Cy7-conjugated anti-mouse Ly6G (1 μg/ml; RB6-8C5, eBioscience, San Diego, CA), PerCP-Cy5.5-conjugated antimouse CD45 (2 μg/ml; 30-F11, eBioscience), APC-conjugated anti-mouse Ly6G (1 μg/ml; 1A8, BioLegend, San Diego, CA), V450-labeled anti-mouse Ly6G (1 μg/ml; 1A8, BD), AF700-conjugated anti-mouse CD11b (2 μg/ml; M1/70, eBioscience), BV510-labeled anti-mouse CD11b (1 μg/ml; M1/70, BioLegend), PE-conjugated anti-mouse FcyRI (1 μg/ml; X54-5/7.1, BioLegend), FITC-labeled anti-mouse FcyRIIa (8.33 μg/ml; Ly17.2, kindly provided by Falk Nimmerjahn), and APC-conjugated anti-mouse FcyRIIb (1 μg/ml; 9E9, BioLegend) were used. In addition, APC-labeled rat IgG2a, κ isotype control (1 μg/ml; RTK2758, BioLegend) and AF700- and PerCP-Cy5.5-conjugated rat IgG2b, κ isotype controls (2 μg/ml; eB149/10H5, eBioscience) were used to identify nonspecific binding. Dead cells were stained with the amine-reactive fixable viability dye eFluor 780 (Life Technologies).

**Assessment of intracellular calcium changes in bone marrow neutrophils**

For staining of cells with the calcium-sensitive compound Fluo-4, isolated bone marrow cells were resuspended to a final concentration of 1 x 10⁷ cells/ml in Dulbecco’s PBS and incubated with 10 μM Fluo-4 AM in the dark for 30 minutes at room temperature. After a wash step with 500 μl Dulbecco’s PBS, the incubation step was repeated to allow intracellular esterases to hydrolyze the acetoxymethyl, unmasking the negatively charged carboxylate groups on the fluorescent compound, making it cell-impermeant and therefore well-retained in the cytoplasm. For detecting changes in intracellular calcium concentration in Ly6G⁺ cells on a BD LSRII flow cytometer (BD Biosciences, Franklin Lakes, NJ), baseline fluorescence was acquired for 15 seconds before the sample tube was removed from the flow cytometer without stopping the measurement and then C5a was added (0.2 nM final concentration), and the tube was quickly reconnected to the flow cytometer. The fluorescence signal was monitored for 2.5 minutes, then 0.5 μg of ionomycin was added as a positive control, and the measurement was continued for another 2.25 minutes. The Fluo-4 signal in Ly6G⁺-gated bone marrow cells, in response to C5a and ionomycin, was transformed into a time-dependent curve using the Kinetics tool within the FlowJo software (version 10; Tree Star, Ashland, OR).

**Neutrophil CD11b upregulation assay**

To investigate the activation potential of neutrophils (Ly6G⁺ cells) from C57BL/6J (wild-type) and C5ar2⁻/⁻ (in C57BL/6J background) mice after stimulation with C5a, changes in the surface expression of the activation marker CD11b were quantified by flow cytometry. In brief, isolated bone marrow cells were incubated in a complete RPMI-1640 medium containing 2.5 nM C5a or no C5a as a control for 30 minutes at 37 °C, 5% carbon dioxide. Cells were washed and stained for Ly6G and CD11b after blocking FcγRs with anti-FcγRII (CD32) and anti-FcγRIII (CD16) antibodies. CD11b expression of C5a-stimulated and nonstimulated Ly6G⁺ cells were determined using a BD LSRII flow cytometer. Changes in CD11b expression were quantified by calculating the relative increase in mean fluorescence intensity of the CD11b signal in response to C5a stimulation.

**ROS release assay**

White 96-microwell plates (Greiner Bio-One, Frickenhausen, Germany) were coated with 1 μg recombinant murine type VII collagen C per well at 4 °C overnight. After blocking with blocking buffer (Dulbecco’s PBS, 1% BSA, 0.05% [w/v] Tween-20) at room temperature for at least 1 hour, 0.2 μg affinity-purified rabbit anti-murine type VII collagen IgG per well was incubated with the plates at room temperature for 1.5 hours. After washing with blocking buffer, 100 μl CL medium (RPMI-1640 medium without phenol red and 10% fetal calf serum and with L-glutamine and 25 mM 4-[2-hydroxyethyl]-1-piperazineethanesulfonic acid) was added to each well, followed by 100 μl of freshly isolated bone marrow cells (5 x 10⁶ cells/ml in CL medium). After the addition of luminol (Sigma-Aldrich, St. Louis, MO), luminescence, corresponding to the amount of ROS released in the form of hydroxide ion, oxygen ion, and hydrogen peroxide, was measured every 2 minutes for 2 hours using a Fluostar Omega ELISA reader (BMG LABTECH, Ortenberg, Germany) at an absorbance rate of up to 3,600 and an average measurement interval of 1 second at 37 °C.

**Isolation and flow cytometric analysis of immune cells from murine ears**

To quantify the number of neutrophils infiltrating the skin, right ears were harvested from diseased C57BL/6J (wild-type) and C5ar2⁻/⁻ (on C57BL/6J background) mice, and immune cells were isolated by mechanical and enzymatic digestion. In brief, the dorsal part of the ear was cut into small fragments and then incubated in complete RPMI-1640 medium containing 1 mg/ml collagenase IV and 50 U/ml DNase I at 37 °C, 300 r.p.m. for 50 minutes. Enzymatic digestion was stopped by adding 0.25 M EDTA in a complete RPMI-1640 medium. The cell suspension and remaining tissue were then washed through a 40-μm cell strainer into a 50-ml tube using the plunger of a 5-ml syringe. Isolated cells were centrifuged and stained for CD45, Ly6G, and CD11b. Surface expression of these antigens was analyzed using a Cytek Aurora spectral analyzer (Cytek Biosciences, Fremont, CA). Autofluorescence was subtracted, and isotype and fluorescence minus one controls were used to identify specific antibody binding.

**SUPPLEMENTARY REFERENCE**

Supplementary Figure S1. C5aR1 (CD88) expression and C5a-induced upregulation of CD11b on BM-derived neutrophils from diseased mice. (a) C5a-mediated activation of neutrophils from diseased mice quantified by upregulation of surface expression of CD11b (n = 10 per group). (b) Representative histograms showing the C5a-induced upregulation of CD11b. (c) Quantitative assessment of C5aR1 (CD88) surface expression in Ly6G⁺ BM cells from diseased mice (n = 10 per group). Shown are combined data from two independent experiments, each performed with five mice per genotype. Differences between groups were analyzed by unpaired two-tailed t-test. BM, bone marrow; MFI, mean fluorescence intensity; n.s., not significant; WT, wild-type. **P < 0.01.

Supplementary Figure S2. The number of neutrophils in the blood and infiltrating immune cells in the ears is elevated in diseased mice of both genotypes (WT and C5ar2⁻/⁻). (a, b) C5ar2⁻/⁻ mice show a tendency to a decreased number of neutrophils in the blood compared with WT mice, although the differences are not significant (a: P = 0.0522; n = 11 for WT and C5ar2⁻/⁻, n = 7 for control; b: n = 10 per group). (c–e) The number of infiltrating immune cells tended to be lower in diseased C5ar2⁻/⁻ mice, but significance was not reached (n = 10 per group; the dotted line in each graph represents the number of immune cells in the ears of naive, nondiseased mice, which is similar in WT and C5ar2⁻/⁻ mice). Differences between groups were analyzed by ordinary one-way ANOVA with Holm-Sidak multiple comparisons test for (a), and by unpaired one-tailed t-test for (b–e). n.s., not significant; WT, wild-type. **P < 0.01.